share_log

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K：重大事件
美股SEC公告 ·  05/31 21:03
牛牛AI助理已提取核心訊息
On May 31, 2024, Novo Integrated Sciences, Inc. announced the approval by its Board of Directors of a Stock Repurchase Program, authorizing the repurchase of up to $5 million of the company's common stock. The repurchases may occur in the open market or through privately negotiated transactions, depending on market conditions and other factors. Additionally, the Board is reviewing the possibility of increasing the repurchase amount, contingent upon the availability of excess funds from a program designed to monetize a Standby Letter of Credit, which is part of the Ophir Collection acquisition strategy. The timing and volume of repurchases will be subject to management's discretion, considering factors such as stock price, market conditions, and the company's capital position. The program does not commit Novo Integrated Sciences to a specific number of shares and may be suspended at any time. The announcement was made in a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.
On May 31, 2024, Novo Integrated Sciences, Inc. announced the approval by its Board of Directors of a Stock Repurchase Program, authorizing the repurchase of up to $5 million of the company's common stock. The repurchases may occur in the open market or through privately negotiated transactions, depending on market conditions and other factors. Additionally, the Board is reviewing the possibility of increasing the repurchase amount, contingent upon the availability of excess funds from a program designed to monetize a Standby Letter of Credit, which is part of the Ophir Collection acquisition strategy. The timing and volume of repurchases will be subject to management's discretion, considering factors such as stock price, market conditions, and the company's capital position. The program does not commit Novo Integrated Sciences to a specific number of shares and may be suspended at any time. The announcement was made in a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.
2024 年 5 月 31 日，Novo Integrated Sciences, Inc. 宣佈其董事會批准了一項股票回購計劃，授權回購公司高達 500 萬美元的普通股。回購可以在公開市場上進行，也可以通過私下談判的交易進行，具體取決於市場條件和其他因素。此外，董事會正在審查增加回購金額的可能性，視一項旨在通過備用信用證獲利的計劃中是否有剩餘資金而定，該計劃是Ophir Collection收購戰略的一部分。回購的時間和數量將由管理層酌情決定，考慮股價、市場狀況和公司資本狀況等因素。該計劃不承諾Novo Integrated Sciences持有特定數量的股份，並可能隨時暫停。該公告是在該公司向美國證券交易委員會提交的8-K表最新報告附錄99.1所附的新聞稿中宣佈的。
2024 年 5 月 31 日，Novo Integrated Sciences, Inc. 宣佈其董事會批准了一項股票回購計劃，授權回購公司高達 500 萬美元的普通股。回購可以在公開市場上進行，也可以通過私下談判的交易進行，具體取決於市場條件和其他因素。此外，董事會正在審查增加回購金額的可能性，視一項旨在通過備用信用證獲利的計劃中是否有剩餘資金而定，該計劃是Ophir Collection收購戰略的一部分。回購的時間和數量將由管理層酌情決定，考慮股價、市場狀況和公司資本狀況等因素。該計劃不承諾Novo Integrated Sciences持有特定數量的股份，並可能隨時暫停。該公告是在該公司向美國證券交易委員會提交的8-K表最新報告附錄99.1所附的新聞稿中宣佈的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。